Target Market Determination
Released
Released
Announcement PDF
Target Market Determination
Made by:
Avecho Biotechnology Limited (ACN 056 482 403) (Company)
Effective Date:
3 April 2023
Product:
Free-attaching options in connection with an entitlement offer under a
prospectus dated 3 April 2023
Important information about this document
This target market determination (TMD) has been prepared by the Company in relation to the following
offers pursuant to the Company’s prospectus dated 3 April 2023 (Prospectus):
(a)
an offer of up to 2,756,804,016 free attaching options exercisable at $0.012 each and expiring
on three years from the date of issue (New Options) in connection with an entitlement offer;
(b)
an offer of up to 75,000,000 options in connection with joint lead manager services (JLM
Options) to be provided by Copeak Corporate Pty Ltd ACN 632 277 144 ATF Peak Asset
Management Unit Trust (Peak); and
(c)
an offer of up to 75,000,000 JLM Options in connection with joint lead manager services to be
provided by CPS Capital Group Pty Ltd ACN 088 055 636 (CPS).
The Company will apply for the New Options and JLM Options to be quoted on ASX.
Capitalised terms used, but not defined, in this TMD have the meaning ascribed to them in the
Prospectus.
Pursuant to the Prospectus:
(a)
Eligible Shareholders who apply for Shares under the Entitlement Offer and Additional Share
Facility are being offered 3 New Options for every 2 Shares subscribed for under the
Entitlement Offer and Additional Share Facility (New Option Offer); and
(b)
sophisticated and institutional who apply for Shares under the Shortfall Offer will be offered 3
options (Shortfall Options) for every 2 Shares subscribed for under the Shortfall Offer
(Shortfall Option Offer);
(c)
Peak is being offered, pursuant to its joint lead manager mandate, 75,000,000 JLM Options
(Peak Offer); and
(d)
CPS is being offered, pursuant to its joint lead manager mandate, up to 75,000,000 JLM
Options (CPS Offer),
(together, the Offers).
Any recipient of this TMD should carefully read and consider the Prospectus in full and consult their
professional adviser if they have any questions regarding the contents of the Prospectus. Any
recipient of this TMD who wants to acquire New Options, Shortfall Options and JLM Options under the
2
Offers will need to complete the Application Form. There is no cooling off period in respect of the issue
of the New Options, Shortfall Options and JLM Options. This TMD is not a disclosure document for the
purposes of the Corporations Act 2001 (Cth) (Corporations Act), and therefore has not been lodged,
and does not require lodgement, with the Australian Securities and Investments Commission (ASIC).
This TMD has been designed to help our investors understand who the Offers are most suitable for
consistent with their likely objectives, financial situation and needs (target market). This TMD also
describes:
(a)
who the Offers are not suitable for;
(b)
how the Offer is distributed;
(c)
how often the Company will review this TMD and when the next review will be;
(d)
the events and circumstances that could mean the Company need to review whether this TMD
is still appropriate;
(e)
the information the Company would need in order to decide that this TMD is no longer
appropriate; and
(f)
how the Company report information related to this TMD.
This TMD does not take into account your individual objectives, financial situation and needs. It is
important for you to consider these matters and read the Prospectus before you make an investment
decision. The Company is not licensed to provide financial product advice in relation to the New
Options, Shortfall Options and JLM Options.
This TMD is current as at 3 April 2023 and will be withdrawn following the issue of the New Options,
Shortfall Options and JLM Options under the Offers. The Company may review and amend this TMD
at any time.
Target Market
Offer
Target Market
New Option Offer
The Company expects that an investment in New Options under New
Option Offer will be suitable for current investors in the Company:
3449-9542-8898, v. 3
•
who wish to gain further exposure to equities in a
small/mid-cap life science company listed on the ASX by
participating in the Entitlement Offer;
•
who is an Eligible Shareholder under the Entitlement Offer,
being persons who:
o
are registered as a holder of fully paid ordinary
shares in Avecho as at 7:00 pm (AEST) on
Thursday, 6 April 2023;
o
have a registered address in Australia or New
Zealand as noted on the Company’s share register,
or are a Shareholder that the Company has
3
Offer
Target Market
otherwise determined is eligible to participate in the
Entitlement Offer;
•
Shortfall Option Offer
are not in the United States and are not a person
(including nominees or custodians) acting for the
account or benefit of a person in the United States
(to the extent such person holds existing shares for
the account or benefit of such person in the United
States); and
o
are eligible under all applicable securities laws to
participate in the Entitlement Offer; and
who are in a position to pay any subscription amounts
required to take up their Entitlements, in order to be
entitled to the New Options.
The Company expects that an investment in Shortfall Options under
the Shortfall Option Offer will be suitable for:
•
•
Peak Offer and CPS Offer
o
new and existing institutional and sophisticated investors
that are invited to invest in the Company to gain exposure
to equities in a small/mid-cap life science company listed
on the ASX; and
who are in a position to pay any subscription amounts
required to subscribe for New Shares under the Shortfall
Offer, in order to be entitled to the Shortfall Options.
The Company expects that an investment in the Peak Offer and CPS
Offer will be suitable for Peak and CPS, being the joint lead
managers to the Entitlement Offer.
Target Market Details
TMD requirement
Determination
Investment Objectives,
financial situation and needs
Offer
Determination
New Option Offer
The Company expects this offer to be
appropriate for those:
•
•
•
3449-9542-8898, v. 3
looking to increase their level of
investment in the Company;
who are in a financial position to
take up all or part of their
Entitlements; and
looking to diversify their personal
investment
portfolio
by
4
TMD requirement
Determination
increasing their investment in the
Company.
Shortfall Option Offer
The Company expects this offer to be
appropriate for those:
•
•
•
Peak Offer and CPS
Offer
The Company expects this offer to be
appropriate for those:
•
•
•
Investment Timeframe
looking to invest in small/mid-cap
life science company listed on
the ASX;
who are in a financial position to
take up the Shortfall Offer; and
looking
to
diversify
their
investment portfolio.
looking to be rewarded for acting
as lead manager on the
Entitlement Offer and who wish
to hold equity in a small/mid-cap
life science company listed on
the ASX;
who are capable of accepting the
offer in exchange for services;
and
looking
to
diversify
their
investment holdings.
The target market of investors will take a short to medium outlook on
their investment. The Company will apply for quotation of the New
Options, Shortfall Options and JLM Options on ASX and will be
transferable.
Holders of New Options, Shortfall Options and JLM Options will also
have an ability to exercise such Options and trade the underlying
Shares issued on exercise, however, investors should be aware that
such a dealing is only likely to be commercially viable in the event
the trading price of the Shares exceeds the exercise price of the New
Options, Shortfall Options and JLM Options (as applicable) and sale
of the underlying Shares.
Investors with a medium-term outlook will benefit from an ability to
either trade the New Options, Shortfall Options and JLM Options on
the ASX or alternatively exercise the New Options, Shortfall Options
and JLM Options prior to expiry of the New Options, Shortfall Options
and JLM Options increase their shareholding and exposure to the
potential upside in the Company’s Shares into the future.
Given the need to pay the exercise price in order to acquire Shares,
investors in the target market are those in a financial position
sufficient for them to invest their funds on exercise of the New
Options, Shortfall Options and JLM Options over an approximate 3
3449-9542-8898, v. 3
5
TMD requirement
Determination
year time horizon, during which their ability to liquidate their New
Options, Shortfall Options and JLM Options in the Company may be
limited by a lack of liquidity in the New Options, Shortfall Options and
JLM Options and by the trading price of the underlying Shares.
Investment Metrics
While the Company does not have an established eligibility
framework for investors based on metrics such as age, expected
return or volatility, it is expected that the target market of investors
will be able to withstand potential fluctuations in the value of their
investment. The New Options, Shortfall Options and JLM Options
offer no guaranteed income or capital protection.
Risk
The Company considers that, while the issue price of the New
Options and Shortfall Option is free and a nominal amount is payable
for the issue of the JLM Options, an investment in the Company
offered in connection with the Prospectus (for example, through the
exercise of the New Options, Shortfall Options and JLM Options)
should be considered highly speculative, such that an investment in
the Company is not appropriate for an investor who would not be able
to bear a loss of some or all of the investment. Investors should also
have a sufficient level of financial literacy and resources (either alone
or in conjunction with an appropriate adviser) to understand and
appreciate the risks of investing in New Options, Shortfall Options
and JLM Options as an asset class generally and the more specific
risks of investing in an Australian listed life science company.
Distribution Conditions
The New Option Offer is being made directly to Eligible Shareholders
who apply for Shares under the Entitlement Offer and Additional
Share Facility.
The Prospectus includes jurisdictional conditions on eligibility. The
Company will also include on its web landing page for the New Option
Offer a copy of this TMD and require that Eligible Shareholders
confirm that they meet the eligibility criteria of the expected target
market outlined in this TMD.
To the extent any entitlement to New Options is not taken up by
Eligible Shareholders under the New Option Offer, the balance of any
shortfall of Shares and Shortfall Options after the close of the
Entitlement Offer and Additional Share Facility may be placed by the
Company to sophisticated and institutional investors within 3 months
of the Closing Date pursuant to the Shortfall Offer.
The Company considers that these distribution conditions will ensure
that persons who invest in New Options and Shortfall Options fall
within the target market in circumstances where personal advice is
not being provided to those persons by the Company.
Review Triggers
3449-9542-8898, v. 3
The New Options, Shortfall Options and JLM Options are being
offered for a limited offer period set out in the Prospectus, after the
conclusion of which the New Options, Shortfall Options and JLM
6
TMD requirement
Determination
Options will no longer be available for investment by way of issue. It
follows that the TMD will only apply in the period up to the issue of
the New Options, Shortfall Options and JLM Options (Offer Period)
at which point the TMD will be withdrawn.
To allow the Company to determine whether circumstances exist that
indicate this TMD is no longer appropriate to the New Options,
Shortfall Options and JLM Options and should be reviewed, the
following review triggers apply for the Offer Period:
Review Period
(a)
a new offer of New Options, Shortfall Options and JLM
Options that requires preparation of a disclosure document
is made after completion of the Offer Period;
(b)
the Company significantly changes the eligibility criteria for
the Offers;
(c)
the Company re-issues the Prospectus;
(d)
the Company receives a significant number of complaints in
relation to the TMD and its contents;
(e)
the Company identifies an instance where the Offers have
been made or accepted outside of the target market;
(f)
any event or circumstance that would materially change a
factor taken into account in making this TMD;
(g)
the existence of a significant dealing of the New Options,
Shortfall Options and JLM Options that is not consistent with
this TMD. The Company does not consider that an on-sale
of the New Options, Shortfall Options and JLM Options on
market is a significant dealing;
(h)
ASIC raises concerns with the Company regarding the
adequacy of the design or distribution of the New Options,
Shortfall Options and JLM Options or this TMD; and
(i)
material changes to the regulatory environment that applies
to an investment in the New Options, Shortfall Options and
JLM Options.
If a review trigger occurs during the Offer Period, the Company will
undertake a review of the TMD within 10 business days in light of the
review trigger.
The Company will otherwise complete a review of the TMD 12
months following its issue and then every 12 months after that period
until such time as the TMD is withdrawn.
Information Reporting
3449-9542-8898, v. 3
The Company records all complaints that it receives about the
Offers or this TMD. If the Company believes that the Offers have
7
TMD requirement
Determination
been made or accepted by a person who does not fit within this
TMD, we will report this to ASIC within 10 business days.
The reporting requirements of all distributors are set out in the table
below:
Reporting
Requirement
Period for
reporting to the
Company by the
distributor
Whether the
distributor received
complaints about
the New Options,
Shortfall Options
and JLM Options.
•
•
3449-9542-8898, v. 3
For such time
as the duration
of the Offer
Period remains
open, within 10
business days
after the end of
each quarter.
Within 10
business days
after the end of
the Offer
Period.
Information to be
provided
•
•
The number of
complaints
received.
A summary of
the nature of
each complaint
or a copy of
each complaint.
A significant dealing
of the New Options,
Shortfall Options
and JLM Options
that is not
consistent with this
TMD.
As soon as
reasonably
practicable after the
significant dealing
occurs, but in any
event no later than
10 business days
after the significant
dealing occurs.
•
A summary of the
steps taken by the
distributor to ensure
that its conduct was
consistent with this
TMD.
Within 10 business
days after the end
of the close of the
Offer Period of New
Options, Shortfall
Options and JLM
Options (which will
occur upon the date
the New Options,
Shortfall Options
and JLM Options
are issued) in
A summary of the
steps taken by the
distributor to ensure
that its conduct was
consistent with this
TMD.
•
Details of the
significant
dealing.
Reasons why
the distributor
considers that
the significant
dealing is not
consistent with
this TMD.
8
TMD requirement
Determination
accordance with the
Prospectus.
Contact Details
Contact details in respect of this TMD for the Company are:
Paul Gavin
Chief Executive Officer
Avecho Biotechnology Limited
Email: pgavin@avecho.com.au
3449-9542-8898, v. 3
Share your feedback
Discover